New therapies for gout

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 325-337

  Crittenden, Daria B ^a,b   Pillinger, Michael H ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

BCX4208; colchicine; febuxostat; interleukin 1 ; lesinurad; pegloticase

Indexed keywords

ALLOPURINOL; CANAKINUMAB; COLCHICINE; FEBUXOSTAT; INTERLEUKIN 1BETA; LESINURAD; LOSARTAN; PEGLOTICASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRIAMCINOLONE; ULODESINE; URATE;

CINCA SYNDROME; CRYOPYRIN ASSOCIATED PERIDIC FEVER SYNDROME; DIARRHEA; DIETARY INTAKE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GENE MUTATION; GOUT; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CYTOKINES; DRUG APPROVAL; GOUT; GOUT SUPPRESSANTS; HUMANS; PREVALENCE; UNITED STATES;

EID: 84873033603     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-080911-105830     Document Type: Review

References (61)

1. Zhu Y, Pandya BJ, Choi HK. 2011. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 63:3136-41
2. Keenan RT, O'Brien WR, Lee KH, et al. 2011. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am. J. Med. 124:155-63
3. Hartung EF. 1954. History of the use of colchicum and related medicaments in gout; with suggestions for further research. Ann. Rheum. Dis. 13:190-200
4. Nuki G. 2008. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr. Rheumatol. Rep. 10:218-27
5. Molad Y. 2002. Update on colchicine and its mechanism of action. Curr. Rheumatol. Rep. 4:252-56
6. Terkeltaub RA, Furst DE, Digiacinto JL, et al. 2011. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 63:2226-37
7. Ahern MJ, Reid C, Gordon TP, et al. 1987. Does colchicine work? The results of the first controlled study in acute gout. Aust. N. Z. J. Med. 17:301-4
8. Terkeltaub RA, Furst DE, Bennett K, et al. 2010. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 62:1060-68
9. Nidorf M, Thompson PL. 2007. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am. J. Cardiol. 99:805-7
10. Crittenden DB, Lehmann RA, Schneck L, et al. 2012. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J. Rheumatol. 39:1458-64
11. Martinon F, Petrilli V, Mayor A, et al. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-41
12. Chen CJ, Shi Y, Hearn A, et al. 2006. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J. Clin. Invest. 116:2262-71
13. Martinon F. 2010. Update on biology: uric acid and the activation of immune and inflammatory cells. Curr. Rheumatol. Rep. 12:135-41
14. Martin WJ, Shaw O, Liu X, et al. 2011. Monosodium urate monohydrate crystal-recruited noninflammatory monocytes differentiate intoM1-like proinflammatory macrophages in a peritoneal murine model of gout. Arthritis Rheum. 63:1322-32
15. Amaral FA, Costa VV, Tavares LD, et al. 2012. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B4 in a murine model of gout. Arthritis Rheum. 64:474-84
16. Goldbach-Mansky R, Kastner DL. 2009. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J. Allergy Clin. Immunol. 124:1141-49; quiz 50-51
17. Goldbach-Mansky R. 2012. Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin. Exp. Immunol. 167:391-404
18. Hoffman HM, Throne ML, Amar NJ, et al. 2008. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58:2443-52
19. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. 2009. Use of canakinumab in the cryopyrinassociated periodic syndrome. N. Engl. J. Med. 360:2416-25
20. Neogi T. 2010. Interleukin-1 antagonism in acute gout: Is targeting a single cytokine the answer? Arthritis Rheum. 62:2845-49
21. Ilaris package insert. http://www.pharma.us.novartis.com/product/pi/pdf/ ilaris.pdf
22. Schlesinger N, Alten RE, Bardin T, et al. 2012. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann. Rheum. Dis. 71:1839-48
23. Becker MA, Schumacher HR Jr, Wortmann RL, et al. 2005. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353:2450-61
24. Zhang W, Doherty M, Bardin T, et al. 2006. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65:1312-24
25. Hamburger M, Baraf HS, Adamson TC 3rd, et al. 2011. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad. Med. 123:3-36
26. SchlesingerN, Mysler E, Lin HY, et al. 2011. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann. Rheum. Dis. 70:1264-71
27. Arcalyst R-package insert. http://www.regeneron.com//ArcalystPI-US- Summary-EMEA/Arcalyst% 0PI-June-2010r3-1.pdf
28. Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. 2012. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 64:876-84
29. SchumacherHRJr, Evans RR, Saag KG, et al. 2012. Rilonacept (interleukin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res. 64:1462-70
30. Kineret R-package insert. http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm094409.pdf
31. So A, De Smedt T, Revaz S, Tschopp J. 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9:R28
32. Chen K, Fields T, Mancuso CA, et al. 2010. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin. Arthritis Rheum. 40:210-14
33. Tran AP, Edelman J. 2011. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int. J. Rheum. Dis. 14:e33-37
34. Becker MA, Schumacher HR, Espinoza LR, et al. 2010. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res. Ther. 12:R63
35. Uloric package insert. http://www.uloric.com
36. Tatsuo H, Iwao O. 2011. A repeated oral administration study of febuxostat (TMX-67), a non-purineselective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J. Clin. Rheumatol. 17:S27-34
37. Fitz-Patrick D, Drummond W, Pappas J, Hollister AS. 2010. Effects of a purine nucleoside phosphorylase inhibitor, BCX4208, on the serum uric acid concentrations in patients with gout. Arthritis Rheum. 62(Suppl. 10):S63 (Abstr.)
38. Hollister AS, Becker MA, Terkeltaub R, et al. 2011. BCX4208 synergistically lowers serum uric acid (sUA) levels when combined with allopurinol in patients with gout: results of a phase 2 dose-ranging trial. Arthritis Rheum. 63(Suppl. 10):S397 (Abstr.)
39. WuXW, Muzny DM, Lee CC, et al. 1992. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J. Mol. Evol. 34:78-84
40. Kissel P, Lamarche M, Royer R. 1968. Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin. Nature 217:72-74
41. Richette P, Briere C, Hoenen-Clavert V, et al. 2007. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J. Rheumatol. 34:2093-98
42. Sundy JS, Ganson NJ, Kelly SJ, et al. 2007. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum. 56:1021-28
43. Sundy JS, Baraf HS, Yood RA, et al. 2011. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306:711-20
44. Hamburger SA, Lipsky P, Khanna D, et al. 2011. Safety and efficacy of long-term pegloticase (Krystexxa) treatment in adult patients with chronic gout refractory to conventional therapy. Ann. Rheum. Dis. 70(Suppl. 3):105 (Abstr.)
45. Hershfield MS, Roberts LJ, Ganson NJ, et al. 2010. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc. Natl. Acad. Sci. USA 107:14351-56
46. Krystexxa package insert. http://www.krystexxa.com
47. Perez-Ruiz F, Herrero-Beites AM, Carmona L. 2011. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis. Arthritis Rheum. 63:4002-6
48. Choi HK, Al-Arfaj AM, Eftekhari A, et al. 2009. Dual energy computed tomography in tophaceous gout. Ann. Rheum. Dis. 68:1609-12
49. Enomoto A, Kimura H, Chairoungdua A, et al. 2002. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447-52
50. YehL, ShenZ, KerrB, et al. 2009. RDEA594: a potentURAT1inhibitorwithout affecting other important renal transporters, OAT1 and OAT3. Ann. Rheum. Dis. 68(Suppl. 3):320 (Abstr.)
51. Tan PK, Hyndman D, Liu S, et al. 2011. Lesinurad (RDEA594), a novel investigational uricosuric agent for hyperuricemia and gout, blocks transport of uric acid induced by hydrochlorothiazide. Ann. Rheum. Dis. 70(Suppl. 3):187 (Abstr.)
52. Perez-Ruiz F, Sundy J, Krishnan E, et al. 2011. Efficacy and safety of of lesinurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: randomized, double-blind, placebo-controlled, Phase 2B study. Ann. Rheum. Dis. 70(Suppl. 3):104 (Abstr.)
53. Fleischmann R, Shen Z, Yeh L-T, et al. 2011. Lesinurad (RDEA594), a novel uricosuric agent, in combination with febuxostat shows significant additive urate lowering effects in gout patients with 100% response achieved for all combination dose regimens. Ann. Rheum. Dis. 70(Suppl. 3):188 (Abstr.)
54. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/results?term=RDEA594, accessed September 2012
55. Choi HK, Liu S, Curhan G. 2005. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the ThirdNationalHealth and NutritionExamination Survey. Arthritis Rheum. 52:283-89
56. Zhang Y, Chen C, Choi H, et al. 2012. Purine-rich foods intake and recurrent gout attacks. Ann. Rheum. Dis. 71:1448-53
57. Choi HK, Atkinson K, Karlson EW, et al. 2004. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277-81
58. Choi HK, Willett W, Curhan G. 2010. Fructose-rich beverages and risk of gout in women. JAMA 304:2270-78
59. Zhu Y, Zhang Y, Choi HK. 2010. The serum urate-lowering impact of weight loss amongmen with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxf.) 49:2391-99
60. Dalbeth N, Gracey E, Pool B, et al. 2010. Identification of dairy fractions with anti-inflammatory properties in models of acute gout. Ann. Rheum. Dis. 69:766-69
61. Dalbeth N, Wong S, Gamble GD, et al. 2010. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann. Rheum. Dis. 69:1677-82